title: The initial clinical experience of 1819 physicians in maintaining anesthesia with propofol: characteristics associated with prolonged time to awakening.
abstract: In October 1989, propofol underwent Phase IV Food and Drug Administration testing that involved 25,981 patients, 1722 institutions, and 1819 anesthesiologists. Participants were 18-80 yr of age and ASA physical status I-III; they could not have a continuing pregnancy or prior adverse anesthetic experience. Anesthesiologists completed detailed forms to describe their use of propofol in this three-step study: propofol for induction only (Step 1), for induction and then maintenance by intermittent bolus injection (Step 2), or for continuous infusion (Step 3). In early 1992, our group of anesthesiologists and epidemiologists analyzed the resulting data base. We evaluated data from 14,882 patients (8095 given bolus injections and 6787 given continuous infusion) to determine factors predicting prolonged time (> 15 min after cessation of all anesthesia) to awakening, one measure of recovery from anesthesia. The incidence of prolonged awakening was 6.8% (1016 patients); the median and mean (+/- SD) times to awakening were, respectively, 5 min and 7.2 +/- 7.3 min. The following variables were associated (P < 0.05) with prolonged awakening from propofol maintenance anesthesia: a total dose of propofol > 8 mg/kg, male gender, endotracheal intubation, age > 65 yr, abdominal surgery, continuous infusion of propofol, and concomitant use of isoflurane or benzodiazepines. These results support the clinical impression that recovery from propofol anesthesia is remarkably rapid; although the vast majority of physicians participating in this study were using propofol for maintenance for the first time, only 6.8% of patients had awakening times exceeding 15 min.
authors.affiliation: Department of Anesthesia and Critical Care, University of Chicago, Illinois 60637.
authors.forename: J L
authors.initials: JL
authors.lastname: Apfelbaum
authors.forename: T H
authors.initials: TH
authors.lastname: Grasela
authors.forename: C C
authors.initials: CC
authors.lastname: Hug
authors.forename: C H
authors.initials: CH
authors.lastname: McLeskey
authors.forename: M L
authors.initials: ML
authors.lastname: Nahrwold
authors.forename: M F
authors.initials: MF
authors.lastname: Roizen
authors.forename: T H
authors.initials: TH
authors.lastname: Stanley
authors.forename: R A
authors.initials: RA
authors.lastname: Thisted
authors.forename: C A
authors.initials: CA
authors.lastname: Walawander
authors.forename: P F
authors.initials: PF
authors.lastname: White
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000762:Anesthesia Recovery Period; D000771:Anesthesia, Intravenous; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D015742:Propofol; D013997:Time Factors
chemical_list: D015742:Propofol